School of Systems Biology, George Mason University, Fairfax, VA, United States.
Research Centre for Medical Genetics, Moscow, Russia.
Front Immunol. 2022 Mar 21;13:705379. doi: 10.3389/fimmu.2022.705379. eCollection 2022.
Recent studies suggest that asthma may have a protective effect on COVID-19.We aimed to investigate the causality between asthma and two COVID-19 outcomes and explore the mechanisms underlining this connection.
Summary results of GWAS were used for the analyses, including asthma (88,486 cases and 447,859 controls), COVID-19 hospitalization (6,406 hospitalized COVID-19 cases and 902,088 controls), and COVID-19 infection (14,134 COVID-19 cases and 1,284,876 controls). The Mendelian randomization (MR) analysis was performed to evaluate the causal effects of asthma on the two COVID-19 outcomes. A cross-trait meta-analysis was conducted to analyze genetic variants within two loci shared by COVID-19 hospitalization and asthma.
Asthma is associated with decreased risk both for COVID-19 hospitalization (odds ratio (OR): 0.70, 95% confidence interval (CI): 0.70-0.99) and for COVID-19 infection (OR: 0.83, 95%CI: 0.51-0.95). Asthma and COVID-19 share two genome-wide significant genes, including at the 9q34.2 region and at the 12q24.13 region. The meta-analysis revealed that and contain variants with pleiotropic effects on both COVID-19 and asthma.
In conclusion, our results suggest that genetic liability to asthma is associated with decreased susceptibility to SARS-CoV-2 and to severe COVID-19 disease, which may be due to the protective effects of ongoing inflammation and, possibly, related compensatory responses against COVID-19 in its early stage.
最近的研究表明,哮喘可能对 COVID-19 具有保护作用。本研究旨在探讨哮喘与 COVID-19 两种结局之间的因果关系,并探索这种关联的潜在机制。
采用全基因组关联研究的汇总结果进行分析,包括哮喘(88486 例病例和 447859 例对照)、COVID-19 住院(6406 例 COVID-19 住院病例和 902088 例对照)和 COVID-19 感染(14134 例 COVID-19 病例和 1284876 例对照)。采用孟德尔随机化(MR)分析评估哮喘对 COVID-19 两种结局的因果效应。进行跨性状荟萃分析,以分析 COVID-19 住院和哮喘共同存在的两个基因座内的遗传变异。
哮喘与 COVID-19 住院风险降低相关(比值比(OR):0.70,95%置信区间(CI):0.70-0.99)和 COVID-19 感染风险降低相关(OR:0.83,95%CI:0.51-0.95)。哮喘和 COVID-19 共享两个全基因组显著基因,包括 9q34.2 区域的 和 12q24.13 区域的 。荟萃分析表明 和 包含对 COVID-19 和哮喘均具有多效性影响的变异。
总之,我们的研究结果表明,哮喘的遗传易感性与 SARS-CoV-2 的易感性降低以及 COVID-19 严重疾病的易感性降低有关,这可能是由于持续的炎症的保护作用,以及可能与 COVID-19 早期相关的代偿反应。